Santhera Doubles Revenue on AGAMREE® Expansion, Eyes APAC Growth…

Event summary

Santhera's H1 2026 revenue surged 101% YoY to CHF 48.3M, driven by AGAMREE® sales growth and a CHF 24.2M upfront payment from Nxera Pharma.
AGAMREE® now commercially available in four of five major EU markets after securing pricing agreements in Spain and Italy.
Nxera Pharma deal valued at up to USD 215M, including USD 30M cash and USD 10M equity investment in Santhera.
Operating loss narrowed significantly to CHF 6.6M from CHF 35.4M in H1 2025.
CEO Orlando Oliveira and Chief Commercial Officer Marc Clausse joined leadership team in mid-2026.

The big picture

Santhera's strong H1 2026 performance reflects AGAMREE®'s growing commercial traction and strategic partnerships expanding its global reach. The Nxera Pharma deal positions the company for significant APAC growth, while continued regulatory progress and real-world data support label expansion opportunities. The leadership transition and narrowing operating loss signal a shift toward sustainable commercialization.

What we're watching

Market Expansion: Whether Santhera can sustain AGAMREE®'s momentum in newly launched EU markets and expand access in France by 2028.
APAC Growth: The pace at which Nxera Pharma advances AGAMREE® regulatory approvals in Japan and other APAC territories.
Financial Stability: How Santhera manages cash flow through H1 2027 amid inventory purchases and mandatory German price reductions.